Savara Inc (NASDAQ:SVRA) Director Yuri Pikover bought 3,734 shares of Savara stock in a transaction on Thursday, March 29th. The shares were purchased at an average cost of $9.00 per share, with a total value of $33,606.00. Following the completion of the purchase, the director now directly owns 153,734 shares in the company, valued at $1,383,606. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of SVRA stock traded down $0.01 during midday trading on Monday, reaching $9.19. 111,927 shares of the company were exchanged, compared to its average volume of 171,195. Savara Inc has a 12 month low of $4.60 and a 12 month high of $17.19. The company has a market capitalization of $281.49, a price-to-earnings ratio of -5.15 and a beta of 0.04. The company has a current ratio of 16.28, a quick ratio of 16.28 and a debt-to-equity ratio of 0.13.
Savara (NASDAQ:SVRA) last released its quarterly earnings results on Wednesday, March 14th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. equities research analysts predict that Savara Inc will post -1.43 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in the business. Lyon Street Capital LLC raised its position in shares of Savara by 53.4% during the 4th quarter. Lyon Street Capital LLC now owns 779,554 shares of the company’s stock worth $11,569,000 after buying an additional 271,214 shares in the last quarter. Two Sigma Securities LLC bought a new stake in shares of Savara during the 4th quarter worth about $173,000. Goldman Sachs Group Inc. bought a new stake in shares of Savara during the 4th quarter worth about $392,000. Deutsche Bank AG raised its position in shares of Savara by 136,538.5% during the 4th quarter. Deutsche Bank AG now owns 17,763 shares of the company’s stock worth $263,000 after buying an additional 17,750 shares in the last quarter. Finally, Consonance Capital Management LP bought a new stake in shares of Savara during the 4th quarter worth about $40,899,000. Institutional investors own 38.14% of the company’s stock.
A number of research analysts have issued reports on the stock. BidaskClub raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday, February 10th. Canaccord Genuity set a $25.00 target price on shares of Savara and gave the company a “buy” rating in a research note on Friday, February 16th. ValuEngine raised shares of Savara from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 14th. Finally, Ladenburg Thalmann Financial Services assumed coverage on shares of Savara in a research note on Wednesday, January 3rd. They set a “buy” rating and a $35.00 target price for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Savara presently has an average rating of “Hold” and an average target price of $23.58.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.